vs
Side-by-side financial comparison of Chemours Co (CC) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Chemours Co is the larger business by last-quarter revenue ($1.3B vs $708.5M, roughly 1.9× Medpace Holdings, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs -3.5%, a 22.6% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs -2.1%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $92.0M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs -1.2%).
The Chemours Company is an American chemical company that was founded in July 2015 as a spin-off from DuPont. It has its corporate headquarters in Wilmington, Delaware, United States. Chemours is the manufacturer of Teflon, the brand name of polytetrafluoroethylene (PTFE), known for its anti-stick properties. It also produces titanium dioxide and refrigerant gases.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
CC vs MEDP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $708.5M |
| Net Profit | $-47.0M | $135.1M |
| Gross Margin | 11.7% | — |
| Operating Margin | — | 21.6% |
| Net Margin | -3.5% | 19.1% |
| Revenue YoY | -2.1% | 32.0% |
| Net Profit YoY | -261.5% | 15.5% |
| EPS (diluted) | $-0.32 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.3B | $708.5M | ||
| Q3 25 | $1.5B | $659.9M | ||
| Q2 25 | $1.6B | $603.3M | ||
| Q1 25 | $1.4B | $558.6M | ||
| Q4 24 | $1.4B | $536.6M | ||
| Q3 24 | $1.5B | $533.3M | ||
| Q2 24 | $1.6B | $528.1M | ||
| Q1 24 | $1.4B | $511.0M |
| Q4 25 | $-47.0M | $135.1M | ||
| Q3 25 | $46.0M | $111.1M | ||
| Q2 25 | $-380.0M | $90.3M | ||
| Q1 25 | $-5.0M | $114.6M | ||
| Q4 24 | $-13.0M | $117.0M | ||
| Q3 24 | $-32.0M | $96.4M | ||
| Q2 24 | $60.0M | $88.4M | ||
| Q1 24 | $54.0M | $102.6M |
| Q4 25 | 11.7% | — | ||
| Q3 25 | 15.6% | — | ||
| Q2 25 | 17.2% | — | ||
| Q1 25 | 17.3% | — | ||
| Q4 24 | 19.4% | — | ||
| Q3 24 | 19.0% | — | ||
| Q2 24 | 19.8% | — | ||
| Q1 24 | 20.9% | — |
| Q4 25 | — | 21.6% | ||
| Q3 25 | 2.5% | 21.5% | ||
| Q2 25 | -15.4% | 20.9% | ||
| Q1 25 | — | 20.3% | ||
| Q4 24 | -0.1% | 23.4% | ||
| Q3 24 | -2.1% | 21.1% | ||
| Q2 24 | 4.4% | 19.9% | ||
| Q1 24 | 5.1% | 20.4% |
| Q4 25 | -3.5% | 19.1% | ||
| Q3 25 | 3.1% | 16.8% | ||
| Q2 25 | -23.5% | 15.0% | ||
| Q1 25 | -0.4% | 20.5% | ||
| Q4 24 | -1.0% | 21.8% | ||
| Q3 24 | -2.1% | 18.1% | ||
| Q2 24 | 3.9% | 16.7% | ||
| Q1 24 | 4.0% | 20.1% |
| Q4 25 | $-0.32 | $4.65 | ||
| Q3 25 | $0.31 | $3.86 | ||
| Q2 25 | $-2.53 | $3.10 | ||
| Q1 25 | $-0.03 | $3.67 | ||
| Q4 24 | $-0.07 | $3.67 | ||
| Q3 24 | $-0.22 | $3.01 | ||
| Q2 24 | $0.39 | $2.75 | ||
| Q1 24 | $0.36 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $670.0M | $497.0M |
| Total DebtLower is stronger | $4.1B | — |
| Stockholders' EquityBook value | $250.0M | $459.1M |
| Total Assets | $7.4B | $2.0B |
| Debt / EquityLower = less leverage | 16.40× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $670.0M | $497.0M | ||
| Q3 25 | $613.0M | $285.4M | ||
| Q2 25 | $502.0M | $46.3M | ||
| Q1 25 | $464.0M | $441.4M | ||
| Q4 24 | $713.0M | $669.4M | ||
| Q3 24 | $596.0M | $656.9M | ||
| Q2 24 | $604.0M | $510.9M | ||
| Q1 24 | $746.0M | $407.0M |
| Q4 25 | $4.1B | — | ||
| Q3 25 | $4.1B | — | ||
| Q2 25 | $4.1B | — | ||
| Q1 25 | $4.1B | — | ||
| Q4 24 | $4.1B | — | ||
| Q3 24 | $4.0B | — | ||
| Q2 24 | $4.0B | — | ||
| Q1 24 | $4.0B | — |
| Q4 25 | $250.0M | $459.1M | ||
| Q3 25 | $274.0M | $293.6M | ||
| Q2 25 | $228.0M | $172.4M | ||
| Q1 25 | $566.0M | $593.6M | ||
| Q4 24 | $571.0M | $825.5M | ||
| Q3 24 | $643.0M | $881.4M | ||
| Q2 24 | $714.0M | $763.6M | ||
| Q1 24 | $753.0M | $671.5M |
| Q4 25 | $7.4B | $2.0B | ||
| Q3 25 | $7.5B | $1.8B | ||
| Q2 25 | $7.5B | $1.6B | ||
| Q1 25 | $7.4B | $1.9B | ||
| Q4 24 | $7.5B | $2.1B | ||
| Q3 24 | $7.5B | $2.1B | ||
| Q2 24 | $7.2B | $1.9B | ||
| Q1 24 | $8.0B | $1.8B |
| Q4 25 | 16.40× | — | ||
| Q3 25 | 14.96× | — | ||
| Q2 25 | 17.99× | — | ||
| Q1 25 | 7.18× | — | ||
| Q4 24 | 7.11× | — | ||
| Q3 24 | 6.20× | — | ||
| Q2 24 | 5.53× | — | ||
| Q1 24 | 5.27× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $137.0M | $192.7M |
| Free Cash FlowOCF − Capex | $92.0M | $188.1M |
| FCF MarginFCF / Revenue | 6.9% | 26.6% |
| Capex IntensityCapex / Revenue | 3.4% | 0.6% |
| Cash ConversionOCF / Net Profit | — | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $51.0M | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $137.0M | $192.7M | ||
| Q3 25 | $146.0M | $246.2M | ||
| Q2 25 | $93.0M | $148.5M | ||
| Q1 25 | $-112.0M | $125.8M | ||
| Q4 24 | $138.0M | $190.7M | ||
| Q3 24 | $139.0M | $149.1M | ||
| Q2 24 | $-620.0M | $116.4M | ||
| Q1 24 | $-290.0M | $152.7M |
| Q4 25 | $92.0M | $188.1M | ||
| Q3 25 | $105.0M | $235.5M | ||
| Q2 25 | $50.0M | $142.4M | ||
| Q1 25 | $-196.0M | $115.8M | ||
| Q4 24 | $29.0M | $183.0M | ||
| Q3 24 | $63.0M | $138.5M | ||
| Q2 24 | $-693.0M | $103.5M | ||
| Q1 24 | $-392.0M | $147.2M |
| Q4 25 | 6.9% | 26.6% | ||
| Q3 25 | 7.0% | 35.7% | ||
| Q2 25 | 3.1% | 23.6% | ||
| Q1 25 | -14.3% | 20.7% | ||
| Q4 24 | 2.1% | 34.1% | ||
| Q3 24 | 4.2% | 26.0% | ||
| Q2 24 | -44.6% | 19.6% | ||
| Q1 24 | -28.8% | 28.8% |
| Q4 25 | 3.4% | 0.6% | ||
| Q3 25 | 2.7% | 1.6% | ||
| Q2 25 | 2.7% | 1.0% | ||
| Q1 25 | 6.1% | 1.8% | ||
| Q4 24 | 8.0% | 1.4% | ||
| Q3 24 | 5.0% | 2.0% | ||
| Q2 24 | 4.7% | 2.4% | ||
| Q1 24 | 7.5% | 1.1% |
| Q4 25 | — | 1.43× | ||
| Q3 25 | 3.17× | 2.22× | ||
| Q2 25 | — | 1.65× | ||
| Q1 25 | — | 1.10× | ||
| Q4 24 | — | 1.63× | ||
| Q3 24 | — | 1.55× | ||
| Q2 24 | -10.33× | 1.32× | ||
| Q1 24 | -5.37× | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CC
| Titanium Technologies | $563.0M | 42% |
| Thermal And Specialized Solutions | $443.0M | 33% |
| Advanced Performance Materials | $312.0M | 23% |
| Other Non-Reportable Segment | $12.0M | 1% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
